# Phase II Trial of EP4 Receptor Antagonist, AAT-007 (RQ-07; CJ-023,423) in Advanced Solid Tumors

> **NCT02538432** · PHASE2 · WITHDRAWN · sponsor: **University of Maryland, Baltimore**

## Conditions studied

- Prostate Cancer
- Non-Small Cell Lung Cancer
- Breast Cancer

## Interventions

- **DRUG:** RQ-00000007
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT02538432
- **Lead sponsor:** University of Maryland, Baltimore
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2017-06
- **Primary completion:** 2019-12
- **Final completion:** 2021-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** PI No Longer at University of Maryland. Now at Fox Chase
- **Last updated:** 2019-11-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02538432

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02538432, "Phase II Trial of EP4 Receptor Antagonist, AAT-007 (RQ-07; CJ-023,423) in Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02538432. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*